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Neurodegenerative diseases are characterized by the progressive loss of neurons in
different regions of the nervous system. Alzheimer’s disease (AD) and Parkinson’s
disease (PD) are the two most prevalent neurodegenerative diseases, and the symptoms
associated with these pathologies are closely related to the regions that are most
affected by the process of neurodegeneration. Despite their high prevalence, currently,
there is no cure or disease-modifying drugs for the treatment of these conditions.
In the last decades, due to the need for the development of new treatments for
neurodegenerative diseases, several authors have investigated the neuroprotective
actions of naturally occurring molecules, such as resveratrol. Resveratrol is a stilbene
found in several plants, including grapes, blueberries, raspberries, and peanuts. Studies
have shown that resveratrol presents neuroprotective actions in experimental models
of AD and PD, however, its clinical application is limited due to its rapid metabolism
and low bioavailability. In this context, studies have proposed that structural changes in
the resveratrol molecule, including glycosylation, alkylation, halogenation, hydroxylation,
methylation, and prenylation could lead to the development of derivatives with enhanced
bioavailability and pharmacological activity. Therefore, this review article aims to discuss
how resveratrol derivatives could represent viable molecules in the search for new drugs
for the treatment of AD and PD.
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INTRODUCTION
Neurodegenerative diseases encompass a set of pathologies characterized by progressive neuronal
death in specific encephalic regions, which produce different clinical manifestations according
to the location of vulnerable neurons (Fu et al., 2018). This selective neuronal vulnerability has
been associated to the aggregation of misfolded proteins that include: β-amyloid (Aβ) and Tau
in Alzheimer’s disease (AD); α-synuclein (α-syn) in Parkinson’s disease (PD), dementia with Lewy
bodies and multiple system atrophy; huntingtin in Huntington’s disease; TDP-43 in frontotemporal
lobar degeneration and amyotrophic lateral sclerosis; among others (Dugger and Dickson, 2017;
Fu et al., 2018). Among these, AD and PD are considered the most prevalent neurodegenerative
diseases (Mayeux and Stern, 2012; Erkkinen et al., 2018), so they will be the focus of this
review article.
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In 2016, global estimates indicated that 43.8 million people
were living with dementia, of which approximately 60% were due
to AD, varying depending on the country and study methodology
(Erkkinen et al., 2018; Nichols et al., 2019). In this sense, there
was an increase of twice the number of cases of patients with
dementia in 20 years, being more frequent in women than in
men with a ratio of 1.2:1.0 (Prince et al., 2015; Nichols et al.,
2019). On the other hand, it is estimated that in 2016 about
six million people had PD worldwide, 2.4 times higher than
the estimated prevalence for 1990; with a male-to-female ratio
of 1.4–2.0:1.0 (Lee and Gilbert, 2016; Ray Dorsey et al., 2018).
Both genetic predisposition and environmental factors have been
involved in the clinical manifestation of AD and PD, with age
being considered a major risk factor for both diseases (Lee and
Gilbert, 2016; Alzheimer’s Association, 2019).
A progressive loss of functions with the consequent disability
and premature mortality of patients with AD and PD have
important implications for the quality of life of patients and
family members. In this regard, a worldwide estimate of
the disability-adjusted life-years (the sum of years lived with
disability and years of life lost) evidenced that all dementias,
including AD, caused 6.4 million, meanwhile, PD produced
3.2 million in 2016 (Ray Dorsey et al., 2018; Nichols et al.,
2019). In the economic field, the costs associated with the
treatment and care of patients with dementia associated with
AD or other diseases is estimated to reach US $290 billion
in 2019 in the USA (Alzheimer’s Association, 2019). On
the other hand, the direct and indirect cost associated
with PD, including treatment, social security payments and
lost revenue, is estimated at US $52 billion per year only
in the USA (Parkinson’s Foundation, 2019). Finally, it is
important to mention that these data do not include the
millions of dollars invested each year in the search for
new treatments for these diseases (Cummings et al., 2018;
Marshall and Willett, 2018).
Despite the high impact of AD and PD in social and
economic spheres, currently, there is no cure or disease-
modifying treatment for most of the cases (Gitler et al.,
2017). Nowadays, the treatment for these diseases is based on
pharmacological and non-pharmacological strategies aimed to
improve the syndromic picture of these pathologies. Thereby,
acetylcholinesterase inhibitors (e.g., donepezil, galantamine,
and rivastigmine) and N-methyl-D-aspartate (NMDA) receptor
antagonists (e.g., memantine) are used for AD treatment. On
the other hand, drugs that increase the synaptic availability
of dopamine, such as the precursor of this neurotransmitter
(levodopa) and inhibitors of enzymes involved in dopamine
metabolism (e.g., carbidopa, entacapone, rasagiline), as well as
agonists of dopamine receptors (e.g., pramipexole, ropinirole),
are prescribed for patients with PD (Oertel and Schulz, 2016; Van
Bulck et al., 2019).
The development of new treatments to combat
neurodegenerative diseases requires a better understanding
of the underlying pathophysiological processes, elucidating
how genetic alterations interact with environmental factors to
produce neurodegeneration. Thus, alterations of proteostasis,
mitochondrial function, autophagy, redox status, metal and
calcium metabolism, as well as neuroinflammation and
neurogenesis have become potential therapeutic drug targets
that are expected to modify the progression of these illnesses
(Van Bulck et al., 2019; Elkouzi et al., 2019). However, obtaining
an effective and safe drug for these diseases entails great
difficulty considering that not all the molecules evaluated
in preclinical studies are viable during the development of
clinical trials; for example, between 2002 and 2012, there
were 244 drugs registered in the National Institutes of
Health (NIH) for clinical studies, and only one received
permission to be used in patients with AD (Alzheimer’s
Association, 2018). Examples of phase 3 clinical trials that
have failed include those involving the anti-Aβ antibodies
bapineuzumab (Salloway et al., 2014; Vandenberghe et al., 2016)
and solanezumab (Honig et al., 2018), and the inhibitors of
β-secretase and γ-secretase verubecestat (Egan et al., 2018)
and semagacestat (Doody et al., 2013), respectively, which
inhibit the enzymes involved in Aβ production. At the
beginning of 2019, 132 agents were being tested in clinical
trials for AD, including 28 agents being evaluated in 42 phase
3 clinical trials (Cummings et al., 2019), and there is a lot of
expectation regarding the revelation of the results of these
studies. The panorama for the development of new drugs for
the treatment of PD is not very different, and among some
unsuccessful attempts are CEP-1347, a mixed lineage kinases
inhibitor (Shoulson et al., 2007), some adenosine A2A receptor
antagonists such as preladenant, vipadenant and tozadenant
(Pinna, 2014; National Library of Medicine, 2019), isradipine,
a dihydropyridine calcium channel antagonist (Lee et al.,
2017; Royal Pharmaceutical Society, 2019), and inosine, that
is considered to act as an antioxidant and anti-inflammatory
(National Library of Medicine, 2018; National Institute of
Health, 2019).
Several studies made in the last years have focused
on the research of the therapeutic potential of a large
number of natural compounds for neurodegenerative diseases,
especially those derived from plant extracts (Wąsik and
Antkiewicz-Michaluk, 2017). Throughout history, ancestral
and traditional wisdom about the medicinal use of some
plants has been the base for the study of the mechanism
of action and safety of countless extracts and compounds
isolated from plants (Anton et al., 2008; More et al., 2013).
The pharmacological attractiveness of the use of natural
compounds revolves around their reduced side effects and
their multiple target mechanism of action, which is particularly
useful for the prevention or treatment of multifactorial
diseases such as those that produce neurodegeneration (Bagli
et al., 2016; Pohl and Kong Thoo Lin, 2018). Within the
vast diversity of natural compounds that are under study
for their neuroprotective potential, are the polyphenolic
compounds, including resveratrol (RV), curcumin, capsaicin
and epigallocatechin gallate (Zhang et al., 2017; Habtemariam,
2019). With this background, the aim of the current review is
to discuss the neuroprotective effects of RV and its derivatives
in experimental models of AD and PD, addressing if these
substances could lead to the development of new treatments for
neurodegenerative diseases.
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RESVERATROL
Resveratrol (3,4′,5-trihydroxy-trans-stilbene) is a stilbene, a
subclass of phenolic compounds, found in several plants,
including grapes, blueberries, raspberries, and peanuts. The
stilbene structure is composed of 14 carbon basic skeleton and
two phenyl groups linked by an ethene double bond (Figure 1;
He and Yan, 2013; Tsai et al., 2017). Experimental studies
have shown that stilbenoids, such as RV, present antioxidant
and anti-inflammatory activity, leading to neuroprotection
(Figure 1). In this section, we will discuss the neuroprotective
effects of RV in different experimental models (preclinical
studies), exploring its mechanism of action. Also, clinical studies
in AD and PD and limitations of RV use will be reported.
Preclinical Studies
In vitro or animal models can mimic some features from AD
and PD pathophysiology, thus providing information about
potential therapeutic targets and new drugs for the treatment
of these conditions. Both AD and PD are associated with
inflammation and oxidative damage. Therefore, antioxidant
and anti-inflammatory agents may be useful tools for the
development of new treatments against these diseases. In this
context, several studies have demonstrated that RV presents
antioxidant and anti-inflammatory actions. Zhang et al. (2010)
showed that RV protected dopaminergic neurons against
lipopolysaccharide-induced neurotoxicity through the inhibition
of microglial activation and nuclear factor kappa B (NF-κB)
signaling. In agreement, Chen et al. (2017) verified that RV
decreased the mitochondrial oxidative stress and apoptosis
in the hippocampus of mice treated with LPS. Furthermore,
RV and one of its metabolites protect HT22 neuronal cells
against glutamate-induced neuronal oxidative stress through the
induction of nuclear factor erythroid 2-related factor (Nrf2)-
dependent heme oxygenase 1 (HO-1) expression (Kim et al.,
2012; Son et al., 2013). These data are supported by other studies,
as reviewed by Truong et al. (2018), which show that the levels
of key antioxidant transcription factors such as Nrf2, HO-1, and
glutathione S-transferase (GST) are increased by RV. Therefore,
since RV presents antioxidant and anti-inflammatory actions,
several studies have investigated its neuroprotective actions in
experimental models of AD and PD.
Neuroprotective Effects of Resveratrol in Alzheimer’s
Disease
The neuroprotective effects of RV have been investigated in
several in vitro and in vivo experimental models of AD (Feng
et al., 2009, 2013; Karuppagounder et al., 2009; Porquet et al.,
2014; Freyssin et al., 2020; Rao et al., 2020). RV can modify
the underlying pathology of AD by several mechanisms which
may slow the onset and progression of the disease (Ahmed
et al., 2017; Sawda et al., 2017). Among the mechanisms of
action of RV in AD we can highlight its antioxidant action,
reduction of neuroinflammation, inhibition of tauopathy and
Aβ-plaque formation, therefore inhibiting neuronal death and
improving memory (Ahmed et al., 2017). The wide variety of
pharmacological targets of RV may be an advantage in its use as
a neuroprotective agent (Andrade et al., 2019).
Oxidative stress plays an essential role in the pathogenesis
of AD. Increased production of reactive oxygen species
(ROS) associated with mitochondrial dysfunction, altered metal
homeostasis and decreased antioxidant defenses affect synaptic
activity and cause neuron damage in AD. In this context,
antioxidant compounds, like RV may be useful for the prevention
and treatment of the disease (Chen and Zhong, 2014; Tönnies
and Trushina, 2017). Several studies suggest that RV protects
against Aβ-induced oxidative damage in different experimental
AD models in vitro (Conte et al., 2003; Jang and Surh,
2003; Chiang et al., 2018; Wang et al., 2018b) and in vivo
(Karuppagounder et al., 2009; Kong et al., 2019). RV can
exert protection against neuronal oxidative damage in different
ways. It can increase the intracellular antioxidant levels, such
as glutathione (Sharma and Gupta, 2002; Savaskan et al., 2003;
Kwon et al., 2010) and antioxidant enzymes, such as superoxide
dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx)
and HO-1 (Chiang et al., 2018; Lin et al., 2018; Zhao et al.,
2018; Kong et al., 2019), and decrease lipid peroxidation
(Sharma and Gupta, 2002; Kong et al., 2019). Moreover, RV
prevents the disruption of mitochondrial membrane potential,
reducing ROS production in brain tissue (Kwon et al., 2010).
In lymphoblastoid cell lines (LCLs) from AD patients, RV
increased the expression of genes encoding known antioxidants
defenses (CAT, copper chaperone for SOD 1, GST zeta 1) and
anti-aging factor sirtuin-1 (SIRT-1; Cosín-Tomàs et al., 2019).
These results are corroborated by Zhang et al. (2019), which
showed that RV improves learning and memory in rats submitted
to a vascular dementia model, probably due to its antioxidant
actions, represented by increased protein expression of SOD and
a decreased hippocampal content of malondialdehyde (MDA).
Another well-explored mechanism of RV is its ability to
prevent inflammatory response associated with AD. In AD, the
Aβ deposition is known to activate glial cells, including both
astrocytes and microglia, leading to neuroinflammation, which
is often associated with neuronal death (Kinney et al., 2018).
Moreover, evidence suggests that neuroinflammation induced
by reactive microglia reduced Aβ clearance causing synaptic
dysfunction and memory impairment (Wang W. Y. et al.,
2015). In astrocytes, RV inhibits LPS induced production of
inflammatory mediators, including nitric oxide (NO); tumor
necrosis factor-α (TNF-α), interleukins (IL-1β, IL-6, IL-12p40,
IL-23), chemokine monocyte chemotactic protein-1 (MCP-
1) and C-reactive protein (CRP; Wight et al., 2012). Feng
and Zhang (2019) investigated the effects of RV in a model
of inflammatory injury induced by Aβ in murine microglial
cells (BV-2 cells). RV significantly inhibited Aβ-induced
proliferation and activation of BV-2 cells, as well as the release
of the proinflammatory cytokines IL-6 and TNF-α. Several
studies show that the anti-neuroinflammatory effect of RV
is related to the inhibition of NF-κB. In rat astrocytes and
microglial cell lines, RV reduces the inflammation induced by
Aβ1–42 through the inhibition of the NF-κB signal pathway
(Zhao et al., 2018). In rodents, a reduction of NK-κB activation
was observed after RV treatment both in ovariectomized
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FIGURE 1 | Neuroprotective mechanisms described for Resveratrol. ∗Some studies did not evidence any involvement of SIRT-1 in the neuroprotective actions of RV
against MPP+. Symbols: ↓: decrease; ↑: increase. Abbreviations: α-syn: alfa-synuclein; Aβ: amyloid-beta, Akt: protein kinase B, AMPK: AMP-activated protein
kinase, CAT: catalase, COX-2: cyclooxygenase-2, GPx: glutathione peroxidase, GSH: glutathione, HO-1: heme oxygenase 1, IL: interleukins, MCP-1: chemokine
monocyte chemotactic protein-1, NF-κB: nuclear factor kappa B, NO: nitric oxide, p53: tumor protein p53, PI3K: phosphatidylinosi-tol 3-kinase, ROS: reactive
oxygen species, SIRT-1: anti-aging factor sirtuin-1, SOD: superoxide dismutase, TNF-α: tumor necrosis factor-α.
D-galactose rats exposed to Aβ1–42 (Zhao et al., 2015) and
in transgenic mice expressing Aβ/presenilin-1 (Solberg et al.,
2014). Interestingly, some studies demonstrated that ε-viniferin,
a naturally occurring RV dimer, is also protective in experimental
models of AD. This compound improved the cognition of mice
that received an intracerebroventricular injection of Aβ25–35
(Jeong et al., 2010), as well as decreased amyloid deposits,
astrogliosis and microglial activation in APPswePS1dE9 mice
(Caillaud et al., 2019).
The neuroprotective action of RV has also been associated
with its ability to increase the activity of SIRT-1 (Ahmed et al.,
2017), a nicotinamide adenosine dinucleotide (NAD)-dependent
deacetylase that removes acetyl groups from various proteins
(Donmez and Outeiro, 2013). SIRT-1 regulates a wide variety
of biological functions, including embryonic development, cell
differentiation and apoptosis (Borra et al., 2005; Wang et al.,
2018a). In AD, the accumulation of Aβ decreases the levels of
SIRT-1 in neurons (Donmez and Outeiro, 2013; Jęśko et al.,
2017; Xu et al., 2018). In this line, some studies reported that the
preventive action of RV is probably related to the modulation
of SIRT-1 expression and activity in neurons (Lagouge et al.,
2006; Feng et al., 2013). These effects may play an important
role in protecting neurons from oxidative damage, prevent
Aβ toxicity and reduce inflammatory cytokines production
by microglia, contributing to improving memory function
(Gomes et al., 2018).
Another key target of AD is related to the microtubule-
associated protein Tau, which forms insoluble filaments that
accumulate as neurofibrillary tangles in AD and related
tauopathies (Iqbal et al., 2010). Under physiological conditions,
tau regulates the assembly and maintenance of the structural
stability of microtubules (Barbier et al., 2019). In the diseased
brain, however, tau becomes abnormally hyperphosphorylated,
which ultimately causes the microtubules to disassemble, and
the free tau molecules aggregate into paired helical filaments
(Šimíc et al., 2016). RV treatment inhibits tau aggregation
and tau-induced toxicity in neuroblastoma cells and reduces
the levels of phosphorylated tau and synapse loss in the
brain of tau transgenic mice (Sun et al., 2019). Yu et al.
(2018), using transgenic mice that overexpress human tau,
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demonstrated that RV was able to reduce the level of total
hyperphosphorylated tau. According to the authors, these results
can be related to the interruption of late-stage tau aggregation.
Moreover, studies have shown that RV induces the activity of
phosphoseryl/phosphothreonylproteinphosphatase-2A (PP2A),
a highly complex heterotrimeric enzyme that has an important
role in the homeostasis of tau, reducing its phosphorylation
(He et al., 2017; Schweiger et al., 2017). Thus, these data indicate
that RV could be an important botanical compound acting
against Tau phosphorylation.
Some literature data have reported that RV can interfere
with Aβ production, clearance, and aggregation, which is linked
to microglial activation, neuroinflammation, apoptosis and
neuronal death in AD (Jia et al., 2017). In an investigation using a
transgenic model of AD in a C. elegans strain, RV reduces the Aβ-
induced toxicity by acting on proteins involved in proteostasis
and reducing the amount of Aβ aggregates (Regitz et al., 2016).
Reinforcing the effects of RV on the clearance of Aβ, Vingtdeux
et al. (2010) showed that RV activates AMP-activated protein
kinase (AMPK) in neuronal cells and consequently reduces
the Aβ levels and deposition, indicating that AMPK signaling
mediates the amyloidogenic effect of RV.
Cholesterol metabolism is another mechanism that has been
implicated in the pathophysiology of AD. It has been shown
that patients carrying the ε4 allele of the apolipoprotein E
(APOE4) are at a higher risk of developing AD, and it has been
suggested that APOE4 could be a target for the treatment of
this disease (Uddin et al., 2019). In this context, it has been
shown that RV may regulate cholesterol metabolism and/or
APOE4 expression in different experimental models (Thomas
et al., 2014), however, the effects of RV in APOE4 expression and
cholesterol metabolism are not known in the context of AD and
should be better explored by further studies.
Thus, these data postulate that resveratrol is an important
natural compound that could inhibit crucial processes involved
in AD pathophysiology.
Neuroprotective Effects of Resveratrol in Parkinson’s
Disease
In addition to the studies showing that RV could be
neuroprotective against AD, several authors have investigated
its effects in experimental models of PD. Several substances
are known to produce damage in dopaminergic neurons and
have been used in experimental models of PD, including
6-OHDA (6-hydroxydopamine), MPTP (1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine) and rotenone. In this context, in vitro
studies have shown that RV is neuroprotective against the
damage produced by 6-OHDA (Albani et al., 2009; Zhang et al.,
2015), MPP+ (a metabolite from MPTP; Gélinas and Martinoli,
2002; Alvira et al., 2007; Okawara et al., 2007; Bournival et al.,
2009; Zeng et al., 2017) and rotenone (Lin et al., 2014, 2018; Feng
et al., 2015; Wang et al., 2018a). These results are supported by
studies in rodents showing that RV is neuroprotective against
6-OHDA (Jin et al., 2008; Huang et al., 2019), MPTP (Lu et al.,
2008; Anandhan et al., 2010; da Rocha Lindner et al., 2015; Guo
et al., 2016) and rotenone (Gaballah et al., 2016; Zhao et al., 2017;
Palle and Neerati, 2018) counteracting the motor and cognitive
changes induced by these neurotoxins as evidenced by several of
these studies.
Several studies have associated the damage induced by these
neurotoxins with the activation of apoptotic pathways. It has
been shown that RV activates PI3K/Akt, a pro-survival signaling
pathway, increases the ratio Bcl-2/Bax and decreases cytochrome
C release and caspase-3 activation, therefore reducing apoptosis
(Bournival et al., 2009; Zeng et al., 2017; Huang et al., 2019).
Furthermore, several studies have associated the neuroprotective
effects of RV with its antioxidant properties. In this context,
studies have shown that RV decreases ROS production and/or
increases antioxidant defenses after the exposure to MPTP/MPP+
(Okawara et al., 2007; Lu et al., 2008; Anandhan et al., 2010; da
Rocha Lindner et al., 2015; Abolaji et al., 2018) and rotenone
(Gaballah et al., 2016; Lin et al., 2018; Palle and Neerati,
2018). These results are supported by other studies showing
that RV protects against mitochondrial dysfunction induced by
experimental PD, counteracting the changes in mitochondrial
morphology and mitochondrial membrane potential (∆Ψm;
Zeng et al., 2017; Lin et al., 2018), as well as increasing
mitochondrial biogenesis (Peng et al., 2016) and complex-I
activity (Palle and Neerati, 2018).
As previously mentioned, RV is well known for being an
activator of SIRT-1. In addition to the activation of other
signaling pathways such as PI3K/Akt and the inhibition of
caspase-3, studies have also shown that the neuroprotective
effects of RV against rotenone may involve the activation of
SIRT-1 and the suppression of p53 gene transcription, which
is related to the up-regulation of pro-apoptotic proteins and
cell death (Feng et al., 2015; Wang et al., 2018a). It should
be mentioned, however, that other studies did not observe any
involvement of SIRT-1 in the neuroprotective actions of RV
against MPP+ (Alvira et al., 2007; Okawara et al., 2007).
Alpha-synuclein (α-syn) is an aggregate prone protein
that has been closely associated with PD pathophysiology,
contributing to mitochondrial dysfunction, neuroinflammation
and neuronal death (Rocha et al., 2018). In addition to its
neuroprotective effects in experimental models of PD induced by
neurotoxins such as 6-OHDA, MPTP and rotenone, it has been
shown that RV is also protective against the cell death triggered
by α-syn. The neuroprotective effect of RV is related to decreased
levels of ROS after α-syn exposure and seems to also involve the
activation of SIRT-1 since it was blocked after the addition of
sirtinol, a SIRT-1 inhibitor (Albani et al., 2009). The idea that
α-syn may be at least partially involved in the neuroprotective
effects of RV has been also supported by other studies showing
that RV may stimulate the autophagic degradation of α-syn after
SIRT-1 activation (Guo et al., 2016), as well as decrease α-syn
expression in the striatum of mice after MPTP administration
(Liu et al., 2019)
Autophagy is an important intracellular mechanism for
protein degradation and the recycling of damaged proteins
that avoids the accumulation of misfolded proteins that have
been also involved in the pathophysiology of neurodegenerative
diseases (Ghavami et al., 2014). Studies have shown that
experimental parkinsonism is associated with autophagic
dysfunction and that RV exerts neuroprotective effects by
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increasing the autophagic flux through the activation of HO-1
(Lin et al., 2014) and mitogen-activated protein kinase (MAPK)
pathway (Lin et al., 2018).
The neuroprotective effects of RV have been also related to
its anti-inflammatory activity and the regulation of astroglial
activation. Jin et al. (2008) have shown that RV can reverse the
increased expression of cyclooxygenase-2 (COX-2) and TNF-
α in the substantia nigra of rats exposed to 6-OHDA. The
involvement of glial cells in the protective actions of RV against
experimental PD has been also explored. In this sense, Chang
et al. (2013) have shown that RV decreases the expression
of myeloperoxidase in glial cells, an enzyme that can oxidize
NO and inhibit NO-dependent signaling in inflammation sites,
and protected dopaminergic cells against rotenone. Interestingly,
the neuroprotective effects of RV were observed only in
neuron-glia co-cultures, while no protection was observed when
RV was administrated in neurons cultured alone, pointing to an
involvement of glial cells in the neuroprotective actions of RV.
In agreement with these findings, Liu et al. (2019) showed that
RV attenuates astroglial activation in the nigrostriatal pathway
of mice exposed to MPTP. It is interesting to note that the
authors showed that RV could present synergic effects when
administrated in association with the dopamine precursor L-
DOPA, which is still the major treatment available for PD
patients. This is important since the administration of RV could
allow the use of lower doses of L-DOPA, therefore decreasing
its adverse effects, which are one of the major problems in its
clinical use. Finally, it is important to mention that some studies
have found that RV presented better efficacy when administered
in nanoparticles when compared with the administration of free
RV (da Rocha Lindner et al., 2015; Palle and Neerati, 2018),
and further studies should better explore the effects of RV
nanoparticles against neurodegenerative diseases.
Clinical Studies and Limitations in the Use
of Resveratrol
The preclinical evidence previously described supports the idea
that RV is a promising compound for the prevention and
treatment of neurodegenerative diseases, including AD and PD.
Thus, some research groups have conducted clinical studies to
evaluate whether RV is as effective in humans as shown in
animal models of neurodegenerative diseases. These studies are
summarized in Supplementary Table S1.
One of the first studies that evaluated the effects of RV on
AD patients was conducted by Turner et al. (2015). This phase
2 clinical trial (randomized, placebo-controlled, double-blinded)
was conducted in 119 individuals with mild to moderate AD
that received RV 500 mg orally once daily (with dose escalation
ending with 1,000 mg twice daily) or placebo for 52 weeks.
The results evidenced that RV is safe and well-tolerated by the
patients, however, no effects were observed on biomarkers of AD
(plasma levels of Aβ 40 and 42; cerebrospinal fluid (CSF) levels of
Aβ 40 and 42, tau and phosphorylated tau; hippocampal volume
and entorhinal cortex thickness). Although this study did not
show very promising results, the same research group analyzed
samples of CSF and plasma from a subset of AD subjects with
CSF Aβ 42 <600 ng/ml. In this small group of patients, they
observed that RV decreases metalloproteinase (MMP) 9 in CSF,
modulates neuroinflammation, induces adaptive immunity and
attenuates the decline in cognition (Moussa et al., 2017). These
results highlight the promising effect of RV in the modulation of
neuroinflammation since matrix MMPs are a family of enzymes
that degrade components of the extracellular matrix, which is
important for normal blood-brain barrier function.
In another randomized placebo-controlled study, a small
number of mild to moderate AD patients received a mixture
of glucose, malate and a low dose of RV (5 mg/day), or
placebo for 1 year. After treatment, it was possible to observe
less deterioration (measured by specific scales to evaluate AD
progress) in patients that received RV, however, these changes
were not statistically significant (Zhu et al., 2018). Recently,
a double-blind randomized controlled trial with 60 elderly
individuals that received 200 mg/day of RV or placebo for
26 weeks failed to show significant benefits of RV on verbal
memory performance (Huhn et al., 2018). Until the moment, no
clinical trials are evaluating the effects of RV in PD.
The effects of RV intake were also investigated in several
studies performed in humans with different health status. Most
studies conclude that RV is safe in doses up to 5 g per day,
however, some patients may have adverse gastrointestinal effects
(Ramírez-Garza et al., 2018). It is important to highlight that
studies have questioned the therapeutic application of RV due
to its low bioavailability. The poor water solubility, the extensive
first-pass effect, and phase II metabolism, due to its hydroxyl
groups that are a substrate for conjugation reactions, are some
of the reasons for RV reduced bioavailability (Intagliata et al.,
2019). In this context, many researchers have been working
on the design and synthesis of RV derivatives (RVD) with
greater bioavailability (but similar pharmacological properties)
than RV. These compounds are very promising since they could
present better neuroprotective effects than RV in vivo and will be
discussed in the next section.
RESVERATROL DERIVATIVES (RVD)
RV is a small molecule (228 Da), with a quite simple chemical
structure and equipped with several functional groups, that
includes hydroxyphenyl and benzene diol groups, aromatic
rings and a double-bound as a linker. The presence of these
functional groups makes RV an attractive molecule to be
modified into more effective derivatives (Lee et al., 2010;
Li et al., 2016). Numerous synthetic methods can be used
to modify the molecular structure of RV and the most
common structural modifications founded in the literature are:
hydroxylation; amination/amidation/imination; methoxylation;
prenylation; and glycosylation (Figure 2). These structural
modifications can lead to RVD with improved bioavailability
and efficacy. Therefore, in this section, we present and discuss
some studies involving the evaluation of the neuroprotective
effects of RVD in experimental models of neurodegenerative
diseases. After a broad search in the literature, the data that
were found were divided into subgroups depending on the
chemical structure of the derivatives. The main studies are briefly
described in Supplementary Table S2.
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FIGURE 2 | Chemical structure of resveratrol and its analogs.
Hydroxylated Resveratrol Derivatives
Increasing the number of hydroxyl groups on the RV
phenyl rings is an interesting strategy to enhance its water
solubility and pharmacological activity (Saiko et al., 2008;
Latruffe and Vervandier-Fasseur, 2018). In general,
polyhydroxylated derivatives containing less than three
hydroxyl groups in the stilbene portion exhibit very low
oral bioavailability. This was evidenced by Chen W. et al.
(2015) that show that the RVD trans-4,4′-dihydroxystilbene is
slowly absorbed by the oral pathway and has low bioavailability
in rats. However, compounds with four hydroxyl groups,
such as oxyresveratrol and piceatannol (PCA; 3,3′,4,5′-trans-
tetrahydroxystilbene) show a better water solubility, faster
absorption and higher bioavailability than RV (Setoguchi et al.,
2014; Chen et al., 2016). Setoguchi et al. (2014) showed that PCA
is absorbed at levels that were 2-fold higher than RV in rats after
intragastric administration. This study also indicates that PCA
presents a higher metabolic stability than RV that predicts the
best biological activity for PCA.
Following their influence in the pharmacokinetics, it has
been shown that the number and position of additional
hydroxyl groups play a crucial role in the antioxidant and
anti-inflammatory effects of RV (Foti Cuzzola et al., 2012).
For example, Cai et al. (2003) showed that RV analogs,
3,4-dihydroxytrans-stilbene and 4,4-dihydroxytrans-stilbene, are
more effective antioxidants than RV. In the same way,
five hydroxylated resveratrol analogs exerted a 6,600-fold
higher free radical scavenging activity when compared to RV
(Murias et al., 2005).
One of the most studied hydroxylated RVD is the PCA.
Zhang et al. (2018) evaluated the effects of this compound
on D-galactose-induced aging in mice. The results showed
that PCA treatment retained spontaneous motor activity and
improved spatial learning and memory skills, as well as prevented
neuronal loss, reduced oxidative stress and promoted cell
proliferation in the hippocampus and cortex. In hippocampal
neuronal cells, PCA, similar to RV, protected against glutamate
excitotoxicity by inducing HO-1 expression through Nrf-2
activation (Son et al., 2013).
Some studies evaluated the effects of PCA in vitro
experimental models of AD. PCA treatment reduced
intracellular accumulation of ROS and apoptosis induced
by Aβ in the PC12 cell line. The protective effects of
PCA against neuronal death were stronger than RV (Kim
et al., 2007). PCA also displayed anti-amyloidogenic
activity (inhibition of Aβ fibrils formation) and protected
cultured hippocampal neurons against Aβ 25–35 and Aβ
1–42 toxicity, by a mechanism dependent on protein kinase C
(Bastianetto et al., 2009). On the other hand, in experimental
models of PD, PCA increased cell viability of G20119S-
Frontiers in Aging Neuroscience | www.frontiersin.org 7 April 2020 | Volume 12 | Article 103
Arbo et al. Resveratrol Derivatives and Neurodegenerative Diseases
expressing neuronal cells (a leucine-rich repeat kinase-2-linked
Parkinson’s disease model) and decreased the dopaminergic
neurodegeneration, oxidative stress and locomotor deficits in a
Drosophila (Angeles et al., 2016).
Aminated, Amidated and Iminated
Resveratrol Derivatives
Other structural modifications to the RV molecule include
the addition of amine groups and the synthesis of amide and
imine derivatives. Lu et al. (2013) synthesized some amino
RVD and evaluated their effects as anti-AD agents. The
derivatives 2-((4-(3,5-Dimethoxystyryl)phenylamino)methyl)-
4-(dimethylamino)phenol (5 days) and (E)-5-(4-(5-
(Dimethylamino)-2-hydroxy benzyl amino)styryl)-benzene-
1,3-diol (10 days) were the lead compounds for AD treatment
because they significantly inhibited Aβ aggregation, presented
antioxidant activity and moderate acetylcholinesterase
inhibition. Moreover, the 5 days compound can cross the
blood-brain barrier in vitro and has low toxicity in mice.
In the work of Li et al. (2014), 20 imine RVD were designed
as multitarget compounds for AD treatment. Most of the
molecules inhibited Aβ aggregation, acted as antioxidants
and metal chelators, and were neuroprotective against
hydrogen peroxide in neuroblastoma cells. The compound
4-(((2-Hydroxyphenyl)imino)methyl)benzene-1,2-diol was
the most promising agent, being more effective than RV as
a neuroprotectant.
RV amidation has also been shown as a promising strategy for
increasing antioxidant and neuroprotection capacity. According
to Jung et al. (2009), amide derivatives are 2–3 times more
potent as antioxidants than RV and are capable to inhibit
LPS-induced NO generation in microglial cells. The allylamine
analog trans-3,4-Dihydroxy-40-(N-allylaminocarbonyl)stilbene
showed the best protective effect against glutamate excitotoxicity
in primary cortical neuron cells (Jung et al., 2009).
Methoxylated Resveratrol Derivatives
The methoxylation reaction is based on the addition of a
methoxy group to a target chemical structure. Methoxylation
can increase the metabolic stability of the molecule and
the time until the peak plasma concentration is reached
(Chimento et al., 2019). The most explored resveratrol-derived
methoxylated molecule for neuroprotection is pterostilbene
also called 3,5-Dimethoxy-4′-hydroxystilbene or 4-[(1E)-2-(3,5-
Dimethoxyphenyl)ethenyl]phenol, an RV analog that substitutes
two of the three hydroxyl groups with methoxy groups (Cichocki
et al., 2008; Lin et al., 2009; Lange and Li, 2018). This main
structural change increases the lipophilicity and enhances oral
absorption and cellular uptake of pterostilbene in comparison
with RV (Lin et al., 2009). Besides, pterostilbene is considered
a less suitable substrate to human sulfotransferases when
compared to RV, which can increase its metabolic stability and
consequently its bioavailability (Wang and Sang, 2018).
Studies have proven that pterostilbene presents an improved
pharmacokinetic profile when compared to RV. Hougee et al.
(2005) compared the half-life of pterostilbene and RV in
mouse plasma after intravenous administration, being 77.9 and
10.2 min, respectively. Another study demonstrated that animals
exposed to different doses and periods showed that the
bioavailability of pterostilbene was approximately 4-fold greater
than of RV (Kapetanovic et al., 2011). Another methoxylated
synthetic derivative of RV is the trans-3,4,5,40-tetra methoxy
stilbene (DMU 212 or TMS), which demonstrated more
favorable pharmacokinetic properties when compared to RV.
Higher levels of the compound have been found in the
brain, colon mucosae, and small intestine compared to RV
(Sale et al., 2004).
Pterostilbene protects human SH-SY5Y neuroblastoma cells
from H2O2 induced oxidative damage by restoring signaling
pathways involved in cell growth and proliferation (PI3K/Akt
and MAPK/ERK; Song et al., 2015). The authors also
demonstrated that estrogen receptor α (ER-α) is involved
in the neuroprotective actions of pterostilbene. Using the
same cell line, other authors showed that pterostilbene
protects against oxidative stress and mitochondrial dysfunction
caused by hyperglycemia, through a mechanism involving the
activation of Nrf2 signaling and its translocation to the nucleus
(Yang et al., 2017).
In a model of Aβ (Aβ1–42)-induced neuroinflammation
in BV-2 murine microglial cells, pterostilbene decreases the
expression and levels of NO and proinflammatory cytokines
(IL-6, IL-1β, and TNF-α). Furthermore, pterostilbene was able to
inhibit the inflammasome NLRP3/caspase-1 (CASP1) pathway,
being a promising agent for the treatment of AD (Li et al., 2018).
Pterostilbene was more effective than RV in neuromodulating
the deleterious effects of aging and AD. SAMP8 mice, animals
widely used to study sporadic and age-related AD, were fed for
8 weeks with 120 mg/kg of pterostilbene and RV, equivalent
to two glasses of wine. Pterostilbene presented better results
than RV and improved the cognitive function of animals in
the radial arm water maze test. Upregulation of peroxisome
proliferator-activated receptor (PPAR) alpha expression could
be associated with modulation of markers of cellular stress,
inflammation, and AD pathology, such as the expression
manganese superoxide dismutase (MnSOD), transcription of
NF-κB and JNK phosphorylation, all significantly improved by
pterostilbene. Also, high levels of pterostilbene in serum and
brain samples were found in this study, while RV was detected
in low levels in the serum and was undetectable in the brain
(Chang et al., 2012). In the study of Joseph et al. (2008),
19-month-old Fischer 344 rats were fed with a low (2.5 mg/kg)
or a high (10 mg/kg) dose of pterostilbene for 12–13 weeks.
Both diets with pterostilbene were able to reverse the deleterious
effects of aging on the cognitive function, especially the working
memory, in a dose-dependent manner. The best performance of
pterostilbene can be attributed to its increased lipophilicity in
comparison to RV, as a result of the replacement of the hydroxyl
group of RV by a methoxy group in pterostilbene (Cichocki
et al., 2008). Such alteration may increase the bioavailability of
pterostilbene, making its neuroprotective effects more potent.
Interestingly, Hou et al. (2014) have also shown that pterostilbene
presents anti-inflammatory effects and improves the cognitive
function of mice exposed to a model of neuroinflammation,
a key component in the pathophysiology of neurodegenerative
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diseases, represented by the bilateral intrahippocampal injection
of LPS.
Some studies have demonstrated the low toxicity of
pterostilbene in animal models and humans. Ruiz et al.
(2009) evaluated the possible harmful effects of ingesting high
doses of pterostilbene in Swiss mice for a subchronic period.
Animals received pterostilbene at doses of 0, 30, 300, and
3,000 mg/kg body weight/day for 28 days. The authors observed
no mortality, no differences in food or water consumption,
neither changes in histopathological or biochemical parameters
of the animals. On the other hand, a double-blind placebo-
controlled intervention clinical trial evaluated the safety of
long-term pterostilbene administration in humans. The patients
with hypercholesterolemia received pterostilbene at doses of 0,
50, and 125 mg twice a day. At the end of 8 weeks, it was not
observed adverse drug reactions on glucose, renal, and hepatic
markers. Thus, the authors report that doses of pterostilbene up
to 250 mg/day are safe for humans (Riche et al., 2013).
Prenylated Resveratrol Derivatives
Prenylation is the covalent binding reaction of a
hydrophobic/lipid moiety to a molecule of interest. Literature
data indicate that this chemical modification increases the
bioactivity of the backbone compound with no prenylation
(Chen et al., 2014). Prenylated RV derivatives have also
shown promising results for the development of drugs for
AD (E)-3,5,40-Trihydroxy-4-prenylstilbene showed free
radical scavenging, good anti-Aβ aggregation and moderate
inhibition of β-secretase (BACE1), further neuroprotective and
neuritogenic activities. The neuroprotective effect was superior
to that presented by RV and was even similar to the positive
control with quercetin. The replacement of the -OH groups of
RV structure is associated with promising activity presented by
the compound against AD (Puksasook et al., 2017).
The enzyme monoamine oxidase-B (MAO-B) acts on
dopamine degradation when it is recaptured from the
extracellular medium to the cytosol (Thorpe et al., 1987).
MAO-B may also be associated with abnormal production of
γ-aminobutyric acid in reactive astrocytes, thus emerging as a
potential therapeutic target of AD (Park et al., 2019). Two RV
isoprenylation dimer derivatives showed moderate inhibition
of human MAO-B activity. Both compounds also showed high
antioxidant capacity in FRAP, DPPH and ABTS assays. Through
in vitro assays, both derivatives demonstrated low toxicity and
neuroprotective activity in PC12 cells exposed to oxidative
molecules such as H2O2, rotenone, and oligomycin-A, and in
BV2 microglial cells exposed to inflammatory stimulation with
LPS. In addition, the compound 5-((E)-2-(3-(3,5-dihydroxy-
4-(3-methylbut-2-en-1-yl)phenyl)-2-(4-hydroxyphenyl)-2,
3-dihydrobenzofuran-5-yl)vinyl)-2-(3-methylbut-2-en-1-
yl)benzene-1,3-diol presents increased capacity to transpose the
blood-brain barrier, demonstrating the importance of the alkyl
group (Tang et al., 2019).
Glycosylated Resveratrol Derivatives
The glycosylation reaction is characterized by the addition
of one (or more) glycosidic moieties to the molecule. This
process can increase the water solubility and stability of
RV. The RVD glycosylated molecule most exploited for
neuroprotection is polydatin (3,4′,5-Trihydroxystilbene-3-O-
β-D-glucopyranoside), also known as piceid. Polydatin has
the same biological properties as RV, but presents greater
bioavailability and is less susceptible to enzymatic oxidation.
Zhou et al. (2009) investigated the absorption and metabolism
of polydatin in rats after oral administration by gavage at three
different doses (50, 100, and 300 mg/kg). They observed a
dose-dependent absorption and a nonlinearly dose-dependent
metabolism of polydatin in rats. Ding et al. (2014) analyzed
the pharmacokinetics and bioavailability of polydatin in rats
after intravenous and oral administration. The pharmacokinetic
parameters demonstrated dose-dependent behavior regardless
of the route of administration, dose increase reflected an
increase in the terminal half-life of the polydatin. However, the
higher increase in peak plasma concentrations and more rapid
elimination was observed in the intravenous administration
when compared to the oral administration. A comparative
study between polydatin and RV observed that when they were
administrated at the same doses, the serum concentration of
polydatin was 3–4-fold higher than RV. Furthermore, other
authors have shown that polydatin may present a higher oral
absorption than RV (Wang H. L. et al., 2015). A study using
polydatin for the treatment of urate nephropathy in mice
revealed that at doses up to 50 mg/kg, polydatin presented
no side-effects in the liver, kidney, and immune system
(Chen et al., 2013).
As well as RV, polydatin has antioxidant and
anti-inflammatory properties (Fabris et al., 2008; Lanzilli
et al., 2012). Chen Y. et al. (2015) investigated the effects of
polydatin in three classical rodent models of PD, induced by
rotenone, MPTP and 6-OHDA. The treatment with polydatin
prevented motor impairments and changes in oxidative stress
markers (GSH, thioredoxin, MDA, and SOD). Moreover,
the rotenone-induced dopaminergic neurodegeneration was
decreased when the animals received polydatin. In order to
elucidate some of the mechanisms involved in neuroprotection
exhibited by polydatin, one study used human SH-SY5Y
neuroblastoma cells exposed to oxidative stress induced by
dopamine. Polydatin was able to protect the cells against
oxidative damage and such neuroprotection could be associated
with the activation of the MAP kinase pathway (ERK1/2 and
ERK5), since the inhibition of this pathway resulted in a
decreased protective effect of polydatin. The activation of the
dopamine-induced caspase pathway was also inhibited by
polydatin pretreatment (Potdar et al., 2018). In a rat model
of LPS-induced PD, polydatin ameliorated motor dysfunction
and protected dopaminergic neurons through the decrease
of microglial activation and pro-inflammatory mediators.
Furthermore, the levels of p-Akt and Nrf-2 were increased and
the activation of NF-κB was suppressed by polydatin in the
substantia nigra (Huang et al., 2018).
Studies on the effects of glycosylated RVD in AD models
are slightly scarcer. In an in vitro model of AD, polydatin,
as well as RV, showed dose-dependent inhibition on Aβ
25–35 polymerization, which is one of the major characteristics
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of AD (Rivière et al., 2007). Therefore, polydatin and other
glycosylated forms of RV may be promising compounds for
the prevention and treatment of age-associated deficits and
neurodegenerative diseases such as AD and PD.
CONCLUSION AND FUTURE DIRECTIONS
In summary, several pieces of evidence have shown in the
last decades that RV presents neuroprotective actions in
experimental models of AD and PD. However, clinical trials
have failed to demonstrate these actions, probably due to the
low bioavailability of RV, among other pharmacokinetics
characteristics. Therefore, studies have focused on the
development of RVD, which could retain the neuroprotective
properties of RV, but presenting higher bioavailability and
efficacy. In this context, different RVD has been generated,
including hydroxylated, aminated, amidated, iminated,
methoxylated, prenylated and glycosylated derivatives. These
derivatives are neuroprotective in some experimental models of
AD and/or PD, however, more preclinical studies are needed
to understand their mechanisms of action and toxicity before
testing them in clinical trials. It is important to mention
that several authors have coincided in showing that RVD
may be more effective neuroprotectants in preclinical studies
than RV, probably due to their improved pharmacokinetics.
Therefore, RVD could be promising agents for the development
of new treatments against neurodegenerative diseases. The
discovery of new molecules for the treatment of these diseases
could have a great impact worldwide, not only improving
the outcomes of patients but also potentiallydecreasing
the amount of money that is currently spent in their
treatment. It should be mentioned, however, that although
some studies have shown the influence of sex in the
pathophysiology of neurodegenerative diseases (as reviewed
by Ullah et al., 2019), the vast majority of in vivo studies
cited in this review were performed in males. Therefore,
future studies should also evaluate the effect of RV and its
derivatives in female animals, aiming to identify if these
compounds could be effective in both sexes, or if they present
sex-specific effects.
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